Harnessing the power of genomics in hypertension: tip of the iceberg?

Despite the blaze of advancing knowledge on its complex genetic architecture, hypertension remains an elusive condition. Genetic studies of blood pressure have yielded bitter-sweet results thus far with the identification of more than 2,000 genetic loci, though the candidate causal genes and biological pathways remain largely unknown. The era of big data and sophisticated statistical tools has propelled insights into pathophysiology and causal inferences.

Tumor-treating fields and concurrent cisplatin: an demonstration of efficacy in triple-negative breast cancer.

Chemotherapy is commonly used to treat patients with triple-negative breast cancer. Combinations of platinum-based chemotherapies have demonstrated higher rates of pathologic complete responses of triple-negative breast cancer compared to combinations without platinum-based chemotherapies. However, there is a significant increase in general toxicity with the addition of platinum-based regimens.

Molecular profiles of blood from numerous species that differ in sensitivity to acute inflammation.

Vertebrates differ over 100,000-fold in responses to pro-inflammatory agonists such as bacterial lipopolysaccharide (LPS), complicating use of animal models to study human sepsis or inflammatory disorders. We compared transcriptomes of resting and LPS-exposed blood from six LPS-sensitive species (rabbit, pig, sheep, cow, chimpanzee, human) and four LPS-resilient species (mice, rats, baboon, rhesus), as well as plasma proteomes and lipidomes. Unexpectedly, at baseline, sensitive species already had enhanced expression of LPS-responsive genes relative to resilient species.